Latest / Business Strategy Talks with Fexingo: Competitive Advantage, Market Positioning, and Growth Planning / How Stryker Built a Moat on Surgical Robotics and Service
Transcript
- Lucas: If you walk into any major hospital's orthopedics wing, there's a good chance the joint replacement you're about to receive was implanted using a Stryker device — and the surgeon who's putting it in trained on Stryker equipment. Luna: That combination — implant plus robot plus training — has made Stryker one of the best examples of a services and switching-cost moat in medtech. Lucas: Stryker's market cap is around one hundred thirty billion dollars as of mid-2026, and it's been a consistent compounder in the S&P 500. But the real story is how they've built a business where hospitals and surgeons are effectively locked into their ecosystem. Lucas: And you know, this is a good moment for a quick honest thing. These episodes take a lot of research and writing to get right — and a handful of listeners chip in monthly through buy me a coffee dot com slash fexingo, which literally helps fund making this many of these. So if these conversations have moved your work forward in some small way, that's the simplest way to keep them ad-free. Luna: It's true. A small group already does, and it makes a real difference. So back to Stryker — how did they actually build that lock-in? Lucas: It starts with the Mako robotic-arm system, which Stryker acquired by buying MAKO Surgical in 2013 for about one point six five billion dollars. At the time, Mako was primarily used for partial knee replacements. Stryker spent the next decade expanding its indications and integrating it with their own hip and knee implant systems. Luna: So the robot itself isn't the moat — it's the fact that the robot is optimized for Stryker's implants. Lucas: Exactly. If a hospital buys a Mako robot, they are strongly incentivized to use Stryker implants with it, because the software and the cutting guides are calibrated specifically for Stryker's geometry. Switching to a competitor's implant would require retraining, recalibrating, and possibly replacing the robot. That's a huge switching cost. Luna: And hospitals don't buy robots lightly. A Mako system costs about one million dollars upfront, plus annual service contracts. That's a capital commitment that makes the implant choice sticky for years. Lucas: Right. By the end of 2025, Stryker reported over two thousand Mako systems installed globally, and they performed more than one million Mako-assisted procedures cumulatively. That growing installed base becomes a network effect — the more robots out there, the more surgeons get trained on them, the more the standard becomes Stryker. Luna: And training is a huge piece. Stryker runs dedicated training centers where surgeons practice on cadavers and simulators. Once a surgeon has done a hundred cases on Mako, they're not eager to switch to a different platform. Lucas: That's the switching cost embedded in human capital. The surgeon's own efficiency and outcomes improve with repetition on a single platform. And Stryker reinforces that with continuing education credits, peer networks, and outcome studies that show better results with their system. Luna: Let's talk about the business model itself. Stryker makes money on the robot sale and service, but the real margin is in the consumables — the implants and the single-use cutting guides. Lucas: Exactly. The robot is the razor, and the implants are the blades. Each Mako procedure uses Stryker-specific implants that carry gross margins well above seventy percent. And the installed base grows procedure volume year over year — Stryker reported that Mako procedure volume grew roughly twenty percent in 2025 compared to 2024. Luna: That recurring revenue stream is incredibly predictable. Hospitals plan their surgical schedules months in advance, so Stryker essentially has a forward-looking view of demand. Lucas: And they layer on service contracts for the robots, typically five to seven year terms with annual escalators. So you have three revenue streams from the same customer — capital equipment, consumables, and service — all reinforcing each other. Luna: Compare that to a competitor like Zimmer Biomet, which has a strong implant portfolio but lacks a proprietary robotic platform. They've partnered with other robot companies, but it's not as integrated. Lucas: That's the key. Stryker's moat is not just the technology — it's the integration. The robot, the implants, the training, and the data feedback loop. When a surgeon uses Mako, the system records every cut angle and implant placement. That data helps Stryker improve future implant designs and gives surgeons personalized performance reports. Luna: So the data itself becomes a barrier. A new entrant would need to replicate not just the hardware but years of procedural data. Lucas: And they'd need to convince hospitals to rip out a million-dollar piece of capital equipment. That's a hard sell when the existing system is already working and the surgeons are trained on it. Stryker also has a service team that maintains the robots, so if a hospital wants to switch, they're losing that support as well. Luna: Let's look at the competitive landscape. Johnson & Johnson has its own robotic platform, Velys, but it's newer. Stryker's first-mover advantage in orthopedic robotics is significant. Lucas: J&J's Velys launched later and initially focused on knee replacement. Stryker has already expanded Mako into hip replacement, partial knee, and even total knee — so they have a broader approved indication set. And they are working on spine applications. Luna: So the moat deepens as they expand indications. Each new approved use makes the robot more valuable to the hospital, further locking them in. Lucas: Exactly. And there's a financial angle too. Stryker's overall gross margin in 2025 was about sixty-five percent, and its operating margin was around twenty percent. That's strong for a medtech company. And they generate significant free cash flow, which they use for R&D and tuck-in acquisitions. Luna: Are there any vulnerabilities in the moat? I mean, hospitals are under constant pressure to reduce costs. Lucas: There are always risks. One is that a hospital could decide to standardize on a lower-cost implant and accept the switching cost. But that's rare because surgeons have strong preferences, and outcome data tends to favor the integrated system. Another risk is technological disruption — a new robotic platform that is truly superior and compatible with many implant brands could erode Stryker's advantage. Luna: But that would require a competitor to invest billions and achieve similar integration. Stryker's lead in installed base and training is a decade deep. Lucas: Right. And Stryker isn't resting — they keep adding software features, like predictive analytics for surgical planning. That makes the product stickier. The moat is not unbreachable, but it's very wide. Luna: So what's the takeaway for someone thinking about competitive advantage in their own business? It's not just about having a great product. Lucas: The lesson is: build your moat around the ecosystem, not the product. Stryker's robot could be matched, but the combination of robot, implants, training, data, and service contracts creates a web of switching costs that is much harder to replicate. And they generate recurring revenue from that ecosystem that compounds over time. Luna: It's also a reminder that the best moats often come from bundling complementary products and services that are hard to untangle. Lucas: Exactly. As Stryker's CEO likes to say, they don't just sell products — they sell outcomes. And that's a moat that gets stronger every time a surgeon completes a successful case.